The acquisition will diversify Alexion's treatment portfolio beyond drugs targeting the C5 protein, which makes up part of the immune system that can sometimes attack the body's own healthy cells.Alexion last year rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders.